A Neutrophil Extracellular Traps-Related Gene Trait Revealed the Prospective Therapy Strategy of Coronary Atherosclerosis
Zhetao Li,Wansong Zhao,Wenbo Ji,Zhaoshui Li,Kuo Wang,Ting Jiang
DOI: https://doi.org/10.2147/jir.s489847
IF: 4.5
2024-11-28
Journal of Inflammation Research
Abstract:Zhetao Li, 1 Wansong Zhao, 2 Wenbo Ji, 3 Zhaoshui Li, 1 Kuo Wang, 4 Ting Jiang 1 1 Heart Center, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, People's Republic of China; 2 Operating Room Department, Qingdao Municipal Hospital, Qingdao, People's Republic of China; 3 Operating Room Department, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, People's Republic of China; 4 Preventive and Health Care Department, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, People's Republic of China Correspondence: Ting Jiang; Kuo Wang, Email ; Background: Coronary atherosclerosis (CA) is a major cause of coronary artery disease (CHD), with inflammation significantly influencing its pathogenesis. This study explores the role of neutrophil extracellular traps (NETs) in CA to understand their influence on disease progression. Methods: Using the GEO database, we analyzed RNA expression microarray data from CA patients, identifying NET-related differentially expressed genes (NETDEGs) through logistic regression, SVM, and LASSO operator regression analyses. CA samples were categorized into risk subgroups based on gene traits, with further analysis on the biological characteristics and immune cell infiltration of the high-risk subgroup. Additionally, transcription factor (TF)-gene, microRNA (miRNA)-gene, and RNA binding protein (RBP)-gene regulatory networks were investigated, alongside a protein-drug network to propose potential targeting therapies. Expression levels of NETDEGs were validated via qRT-PCR and Western blotting. Results: Three NETDEGs—MMP9, ERN1, and G0S2—were pinpointed as key players in CA development, regulated by TFs, miRNAs, and RBPs. These genes defined high-risk subgroups marked by intense inflammatory signaling and apoptosis. High neutrophil infiltration correlated positively with NETDEG expression in CA samples, supporting their potential as biomarkers. MMP9 emerged as a notable drug target, providing a possible therapeutic avenue. Conclusion: This research highlights an independent NETDEG trait in CA, offering insights into potential biomarkers and therapeutic targets for combating this disease. Keywords: neutrophil extracellular traps, coronary atherosclerosis, biomarker, therapy target As the population ages, the morbidity of coronary atherosclerosis (CA) is increasing annually and has become the leading cause of death worldwide. 1–3 According to a report from the American Heart Association, approximately 10.9% of adults aged 45 years and older and 17.0% of adults aged 65 and older had CA, and approximately 800,000 Americans suffered a myocardial infarction (MI) each year. 4 CA can cause coronary atherosclerotic heart disease, namely, coronary artery disease (CHD), by causing myocardial ischaemia and hypoxia. The main clinical manifestations of CHD contain angina pectoris, myocardial infarction, myocardial fibrosis and sudden coronary death, which is the main reason of death. The treatment of CHD mainly includes lifestyle changes, drug therapy, surgery, and drug treatment, which are the basis of coronary disease control. 5–8 Drug therapy includes lipid-regulating drugs, antiplatelet drugs, anti-myocardial ischaemia drugs, drugs to improve cardiac remodelling and prognosis, as well as thrombolytic drugs and anticoagulants, all of which have their own side effects. Surgical treatment mainly involves coronary revascularization, including percutaneous coronary intervention (PCI) and coronary bypass grafting (CABG). Currently diagnostic tests for CHD include blood tests, electrocardiograms, exercise stress tests, coronary CT angiography and coronary angiography; however, there are no specific biomarkers for realize the early diagnosis and prognosis assessment of CHD. More studies are needed to identify specific biomarkers of CHD to enable the early diagnosis and prognosis assessment of CHD. The inflammatory mechanism runs through the entire process of initiation, progression and complication formation in CA. 9,10 When external stimuli, such as dyslipidemia, hypertension or proinflammation cytokines lead to disorders of the arterial endothelium, they can express more adhesion molecules to promote the adhesion of leukocytes and blood vessel walls. With the accumulation of chronic inflammation, endothelial cells become dysfunctional, allowing low-density lipoprotein and inflammatory cells to enter the endodermis, and smooth muscle cells (SMCs) migrate from the tunica media into the intima and -Abstract Truncated-
immunology